Short answer
HERON THERAPEUTICS, INC. /DE/ (HRTX) filed its Q2 2026 10-Q quarterly report on Aug 10, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $38M (up 1.3% year over year) with net income of −$5M.
Q2 2026 key financials · XBRL
- Revenue
- $38M
- +1.3% YoY · +8.5% QoQ
- Net income
- −$5M
- −130.5% YoY · +32.3% QoQ
- Operating margin
- -5.4%
- Gross margin
- 69.3%
- EPS (diluted)
- −$0.03
- −200.0% YoY · +25.0% QoQ
Source: XBRL data from the HERON THERAPEUTICS, INC. /DE/ (HRTX) Q2 2026 10-Q on SEC EDGAR. USD.
HERON THERAPEUTICS, INC. /DE/ Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Profitability, margin percentages, and quarterly earnings figures not provided
- APONVIE pass-through reimbursement expired March 31, 2026
- APONVIE permanent J-code approved effective April 1, 2026
- SUSTOL commercial availability ending September 30, 2026; CINVANTI patent claims invalidated or found not infringed
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other HERON THERAPEUTICS, INC. /DE/ quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.